Steven Cohen Belite Bio, Inc Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Belite Bio, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 7,311 shares of BLTE stock, worth $511,038. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,311
Previous 7,311
-0.0%
Holding current value
$511,038
Previous $333,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BLTE
# of Institutions
12Shares Held
187KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY148KShares$10.3 Million0.09% of portfolio
-
State Street Corp Boston, MA15.7KShares$1.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$468,3300.0% of portfolio
-
Hrt Financial LP New York, NY5.41KShares$378,0890.0% of portfolio
-
Virtus ETF Advisers LLC New York, NY1.81KShares$126,3090.04% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.74B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...